CD19 chimeric antigen receptor (CAR) T-cells are T-cells that are engineered to target CD19-expressing B-cells and are used to treat refractory diffuse large B-cell lymphoma. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.